- Report
- February 2024
- 175 Pages
Global
From €4760EUR$5,000USD£4,069GBP
- Clinical Trials
- February 2024
- 80 Pages
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- January 2024
- 285 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €10468EUR$10,995USD£8,948GBP
- Report
- March 2019
- 110 Pages
Global
From €3094EUR$3,250USD£2,645GBP
- Report
- March 2021
- 75 Pages
Global
€20946EUR$22,000USD£17,904GBP
- Report
- June 2018
- 15 Pages
Global
From €9521EUR$10,000USD£8,138GBP
Gocovri is a central nervous system (CNS) drug used to treat dyskinesia in patients with Parkinson's disease. Dyskinesia is a condition characterized by involuntary movements of the body, which can be disabling and interfere with daily activities. Gocovri is an extended-release form of amantadine, a drug that has been used to treat Parkinson's disease for decades. Gocovri is the first and only FDA-approved treatment for dyskinesia in Parkinson's disease.
Gocovri is part of a larger market of CNS drugs, which includes treatments for a variety of neurological conditions, such as Alzheimer's disease, multiple sclerosis, and epilepsy. These drugs are used to manage symptoms, slow the progression of the disease, and improve quality of life.
Some companies in the CNS drug market include AbbVie, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more